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ABSTRACT 
 
      Photodynamic therapy (PDT) is a promising approach used in the treatment of cancer, 
age related macular degeneration, psoriasis, and other diseases. Our research is focused 
on the discovery of new photonucleases for use in PDT. This study evaluates the photo-
induced DNA cleaving abilities of a series of acridine and phenazine-based 
chromophores. The extended, aromatic ring systems of these compounds are expected to 
intercalate between adjoining base pairs in the DNA double-helix. Once irradiated, strand 
breakage, or nicking of plasmid DNA is achieved at micromolar concentrations of 
compound (pH 7.0 and 22 °C).  Our scavenger experiments show that this process occurs 
as a result of direct electron transfer to oxygen and/or by means of energy transfer which 
results in the production of singlet oxygen. Three of the photonucleases being examined 
were designed to chelate metal. These exhibited increased levels of DNA photocleavage 
in the presence of copper(II).  
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Introduction 
Photodynamic therapy (PDT) is a promising approach used in the treatment of 
cancer, age related macular degeneration, psoriasis, and other diseases. In PDT, a light 
source is utilized to activate a photosensitizing agent which selectively destroys diseased 
tissue. The patient is administered the photosensitizing compound hours or days before 
the procedure. The compound will be absorbed by cells throughout the body, but it may 
be preferentially retained by tumor cells. It is therefore essential that the compound be 
nontoxic until activated by light. During the procedure, the diseased tissue is irradiated at 
a specific wavelength where the compound absorbs. The compound then causes damage 
to the DNA and other cellular components in the irradiated area, leaving other healthy 
cells intact.  
 The use of light as a therapeutic agent is not a new concept. Light has in fact 
been used for more than three thousand years as a form of medicinal therapy. [1,2]  There 
is evidence that ancient Egyptian, Chinese and Indian civilizations used light to treat 
various diseases including psoriasis, vitiligo, and even skin cancer.[3]  Documents have 
been found from the 2nd century B.C. in which Greeks described the use of 
“heliotherapy” as an efficient means of the “restoration of health”. In the Hindu sacred 
text Atharva-veda, which dates back to 1400 B.C., there is reference to the usage in India 
of seeds from the plant Psoralea corylifolia and sunlight as a treatment for vitiligo.  
Similar references were found in Egyptian writing regarding the use of the plant Ammi 
majus, which was also used to treat vitiligo.  
In 1815, J. F. Calvin wrote about what he referred to as the curing effect that 
sunlight appeared to have on various conditions such as rickets, scrofula, scurvy, 
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rheumatism, paralysis, and muscle weakness.[1] It was not until 1822 when a Polish 
physician, Dr. Sniadecki formally documented the importance of exposure to the sun as a 
means to prevent and cure rickets. The current usage of light in targeted medical therapy 
has its most direct origins at the turn of the nineteenth century.[1]  
In 1900, a German medical student named Oscar Raab found that certain 
wavelengths of light were lethal to microorganisms, such as Paramecium, when 
irradiated in the presence of acridine.[4] Also in that same year, the French neurologist J. 
Prime noted that epilepsy patients, who were receiving the oral medication Eosin, 
developed severe cases of dermatitis in the areas of their body which had been exposed to 
sunlight.[5]  In 1903, Herman von Tappeiner, director of the Pharmacological Institute of 
the Ludwig-Maximilians University in Munich, and A. Jesionek topically applied eosin 
to von Tappeiner’s skin and irradiated the area with white light.[6] Tappeiner noted a 
sensitivity and reddening of the skin in the areas exposed to light where the Eosin had 
been applied. They document this phenomenon and named the process photodynamic 
action, the first known usage of the term.[7]  von Tappeiner is considered to be one of the 
pioneers in the field of photobiology.  
During the same period (the late 1890s), a scientist working in Denmark, Niels 
Finsen, was developing a similar process using light to treat disease.  In 1901, he 
discovered that exposing smallpox pustules to red light would prevent the formation and 
discharge of the pustules.[8] He also discovered that solar ultraviolet light could be used to 
cure cutaneous tuberculosis.  For his efforts, Finsen was awarded the 1903 Nobel Prize in 
medicine. He is also credited with the origin of modern light therapy.   
  3
 
Some of the first compounds found to be effective in phototherapy were 
porphyrins, which continue to be the most widely studied class of photosensitizers.  
Among the first documented studies with these compounds is the work conducted by W. 
Hausmann around 1911.  He used a haematoporphyrin, which he isolated from blood 
samples, and found that upon irradiation with light, red blood cells as well as skin cells 
and paramecia were destroyed.[9]  
The first documented photodynamic therapy studies involving humans are from 
the laboratory of Friedrich Meyer-Betz, a German scientist who in 1913 injected himself 
with a 200 mg sample of haematoporphyrin. He observed that in those areas exposed to 
light, after the haematoporphyrin had been intravenously administered, there was 
significant discomfort and swelling.[10] A report published in 1943 documenting the work 
of Auler and Banzer presented the first successful usage of the photosensitizer 
haematoporphyrin  and light to treat a localized tumor.[11] At that time, there was also a 
growing belief that the compound haematoporphyrin was preferentially taken up by 
tumor cells. This conclusion was based largely on the observation by Auler and Banzer 
that, upon injection with haematoporphyrin IX, the compound accumulated in primary 
and metastatic tumor cells as well as in lymph nodes. They then found that subsequent 
treatment of the tumors with light showed very positive results: those mice with tumors 
tolerated a larger dose of the compound. They concluded that this was probably because 
tumor cells took up significant amounts of the compound, thus protecting other sensitive 
organs from the effects of the radiation damage. [11]  
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In the 1950s, the use of phototherapy became widespread.  The English 
obstetrician Richard Cremer, on the recommendation of a local nurse in Essex, England, 
began using phototherapy as a treatment for jaundice in newborns babies.[12] 
 The idea of haematoporphyrin uptake in humans prevailed until the mid-1950s 
when the Israeli researcher S. Schwartz proposed that this phenomenon might not be due 
to haematoporphyrin itself, but rather due to some impurity present in the mixture being 
employed.  This was attributed to the fact that the mixture had never been completely 
characterized and remained quite difficult to purify.  In his work, Schwartz had injected 
over 150 mice with varying amounts of haematoporphyrin from 10 µg up to 1250 µg. 
After an incubation time of three hours, the mice were exposed to ionizing radiation. 
Those mice receiving intermediate doses of the compound, around 50 µg, showed 
complete destruction of the tumor, while those receiving very high or very low doses did 
not show complete destruction.  Schwartz went through great efforts to purify the 
commercial samples of haematoporphyrin and found that the pure haematoporphyrin was 
a very poor photosensitizer. He then treated the purified haematoporphyrin with acetic 
acid which yielded a product that was a more effective photosensitizer.[13]  Further 
research by R. Lipson et al. working at the Mayo Clinic showed that chemically 
modifying the structure of haematoporphyrin  could increase the selective uptake of the 
compound by cancer cells.[14] They named the resulting compound haematoporphyrin 
derivative (HpD).  This became the first synthetic compound to be employed in the 
localized photo treatment of tumors. Work on this compound continued through the 
sixties and into the early seventies, showing that the selective uptake of HpD could be 
greatly increased if the compound were administered intravenously or intraabdominally, 
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and could serve as a very effective tool for the detection of cancers.  Also, prolonged 
irradiation of tumor cells sensitized with HpD was found to effectively destroy these cells. 
Lipson and his colleagues were able to determine that the HpD derivative they had 
synthesized was actually an aggregate containing many different components, primarily 
composed of several different porphyrin monomers, as well as dimers and several 
oligomers. They discovered that each of these three groups of compounds had very 
different properties and reacted differently in cell culture and had very different degrees 
of efficacy as photosensitizes. The monomers were found to have high fluorescence 
quantum yields but exhibited very poor cellular uptake.  The dimers had better cellular 
uptake capacity, but exhibited relatively low fluorescence quantum yields. The 
aggregates were shown to have very weak fluorescence quantum yields, but were taken 
up most effectively by tumor cells.[14] Then, in 1975, Thomas Doughtery and his 
associates working at the Roswell Park Memorial Cancer Institute in Buffalo, N.Y., 
further purified HpD by removing the monomers and produced the first FDA-approved 
phototherapeutic agent, Photofrin I.[15] They reported that this compound in combination 
with irradiation using red-light stopped mammary tumor growth. It was used for the 
treatment of skin, brain and bladder tumors in humans.[16, 17] It was also employed for the 
temporary relief of other conditions including endobronchial and esophagus 
obstructions.[18]  In 1975, J.F. Kelly reported that the compound proved to be effective in 
the treatment of bladder carcinoma in mice.[19] Then, in 1976, Kelly and associates 
initiated the first human trials with HpD for the diagnosis of cancer. After observing that 
there was significant accumulation of HpD in malignant and premalignant bladder tissue 
but not in healthy tissue, Kelly hypothesized that by attaching a fluorescent chromophore 
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to the HpD molecule, it could be possible to screen patients for the presence of malignant 
tissue.[20] These discoveries were pioneering in the field of photodynamic therapy as a 
means of detecting and eradicating malignancies. 
Once it was realized that haematoporphyrin and HpD were both mixtures with 
components containing very different properties, there was a great deal of interest in 
developing a pure photosensitizing agent. In 1972, I. Diamond and his colleagues 
theorized that by combining the best tumor-localizing and tumor-phototoxic properties of 
porphyrins, it might be possible to design an efficient cancer killing agent.[21] Because of 
its low extinction coefficient and varying levels of purity, Photofrin I required large doses. 
In addition, it was difficult to calibrate usage for individual patients. Also, because of the 
slow cellular uptake and clearance rates, the compound needed to be administered two to 
three days prior to treatment and had lasting side effects which could persist up to six 
weeks following treatment. Irradiation at the wavelength maximum of this compound, 
630 nm, provides poor tissue penetration by the light. Its applications are limited to 
treatment of near surface carcinomas. Effective penetration into tissue is seen at 
wavelengths of 600-800 nm,[22-26] with increasing tissue penetration being in direct 
correlation to increasing wavelength. In 1983, these shortcomings led to the development 
of a more effective version of Photofrin by Kessel and Crow referred to as Photofrin II. 
Today, Photofrin II is the only drug approved by the U.S. FDA for the treatment of 
superficial bladder carcinoma; it is also being used in Canada for similar treatments and 
is approved for use in early lung and esophageal cancers in both Japan and the 
Netherlands.[27] As of March 2006, there were three approved compounds and several 
compounds in clinical trials awaiting approval by the U.S. FDA (Table 1). 
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Sensitizer Trade Name Applicaion / Condition FDA Status 
HpD porfimer Photofrin II Cervical, endobronchichial bladder, 
gastric cancers and brain tumors 
Approved 
BPD-MA 
 
benzoporphyrin derivative monoacid 
Verteporfin/ 
Visudyne 
 
Macular degeneration Approved 
5-ALA 
5-aminolevulinate 
Levulan Actinic keratosis Approved 
hexaminolevulinate 
hydrochloride 
Hexvix Diagnosis, bladder cancer PHASE III 
SnET2 
tin ethyl etiopurpurin 
Photrex Wet macular degeneration PHASE III 
Anecortave acetate Retaane Wet macular degeneration PHASE III 
8-methoxypsoralen Methoxalen T-Cell lymphoma, 
psorasis 
PHASE III 
Dihematoporphyrin 
derivative  
Prednisolone Macular degeneration  PHASE III 
5-ALA methyl 
aminolevulinate 
Metvix Pre-cancerous lesions, actinic keratosis, 
basal cell carcinoma 
PHASE II 
5-ALA benzylester 
5-aminolevulinate benzylester 
Benzix Intestinal cancer PHASE II 
Taporfin Talaporfin Solid tumors PHASE II 
Diethylene glycol 
benzoporphyrin  
Lemuteporfin Prostate hyperplasia PHASE II 
Lutetium texaphyrin Motexafin 
Lutetium 
Stage I & II prostate cancer / recurrent 
prostate cancer 
Completed PHASE I 
M-THPC 
meta-
tetrahydroxyphenylchlorin 
Foscan Prostate and pancreatic tumor PHASE I 
HPPH 3-(4-
hydroxyphenylpropionic acid 
hydrazide HCl 
Photochlor Basal-cell carcinoma PHASE I 
Phthalocyanine-4 Pc 4 Cutaneous/subcutaneous lesions PHASE I 
Silicone phthalocyanine-4 Si Pc4 Actinic keratosis PHASE I 
Lutetium texaphyrin Lutex Cervical, prostate and brain tumors Suspended 
Boronated protoporphyrin BOPP Brain tumor Withdrawn 
(Phase I) 
 
     Table 1 PDT agents and their status as of March 2006. 
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Figure 1 Porphyrin-derivatives and their structures. 
 
Compounds in these classes, and other similar ones, currently under investigation 
as potential photosensitizers are referred to as “second generation” and “third generation” 
photosensitizers. They include other porphyrin derivatives such as phthalocyanines, 
napthalocyanines, and chlorines (Figure 1). A number of the compounds listed in Table 1 
are those in which aminolevulinate derivates are enzymatically converted in vivo to 
protoporphyrin IX. This compound is a precursor to the production of other porphyrins. 
In 1961, Wilkman introduced tetraphenyl porphyrin sulfonate (TPPS) and proposed it as 
a good alternative to HpD. It was suggested that it would have a much better ability to 
localize in tumor cells. Pthalocyanines were first introduced by Ben-Hur et al. in a 1985 
journal article which described the ability of this class of compounds to inhibit tumor 
N
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N
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N
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growth in Chinese hamsters.[28]  Both these compounds can be synthesized with variable 
numbers of sulfonate groups, which allow for specific tuning of the compounds, making 
them more or less water-soluble as desired. This ability has led researchers to investigate 
how different properties and the structure of the compound will affect function. Chlorin 
compounds were first introduced into the area of photodynamic therapy in 1986 by 
Berenbaum and colleagues with a meso chlorin-substituted tetra (meta-hydroxyphenyl) 
chlorin. This compound was suggested to have a favorable selectivity for tumor cells. 
A major advantage in the development of these compounds is that they are well 
characterized. Most are very efficient generators of singlet oxygen and have high 
fluorescence quantum yields which correlate to high λmax absorbance. In addition, any 
new compounds should have a consistent composition inactive until irradiated and be 
chemically stable. These compounds should also exhibit a high selectivity for malignant 
tissues and relatively rapid elimination from healthy tissue.  These factors would help 
alleviate some of the common problems currently experienced by patients undergoing 
photodynamic therapy with Photofrin I and II. A major challenge, however, is that many 
are hydrophobic, which can cause the compounds to aggregate or stack in aqueous 
environments.  As a result, equally important in the development of new drugs is an 
effective delivery system.  There are numerous, proposed systems including polymeric 
particles, oil-dispersions, hydrophilic polymer-photosensitizer conjugates, and 
liposomes.[29-32] 
In PDT, electromagnetic radiation emitted by a light source is absorbed by a 
phototsensitizer giving the singlet state (1P*, Figure 2). The singlet state can undergo 
intersystem crossing to a long-lived triplet state (3P*). The generation of cytotoxic species 
  10
 
can occur from either the single state or the triplet state through two possible pathways, 
know as Type I and II processes (Figure 3).[33] However, because of the significantly 
 
Figure 2 Jablonski Diagram. Once the photosensitizer is irradiated by an appropriate light source, it can 
absorb the energy to give an excited state. The photosensitizer can then react chemically, release the energy 
through fluorescence, or it may undergo intersystem crossing to a lower energy, longer lifetime triplet 
excited state. This energy can decay further back to the ground state through phosphorescence. 
Alternatively, the triplet state may transfer this energy to a nearby species capable of accepting the energy 
such as molecular oxygen which exits in a triplet ground state. 
 
 
longer lifetimes, (τT),  observed for the triplet state, compared to the 10-100 ns lifetimes 
typically seen for the singlet state,[34]  cytotoxic species are most often produced from the 
triplet state. Because the triplet state is a low energy state, it has the advantage of having 
a significantly longer lifetime, usually greater than 500 ns.[35] 
The DNA strand breaks induced by photosensitization can occur as a result of 
three primary mechanisms: 1) photo generation of hydroxyl radicals (•OH; Type I 
pathway), a reactive oxygen species that cleaves DNA by abstracting hydrogen atoms 
from the deoxyribose sugar backbone, 2) electron transfer from the nucleobases, 
specifically guanine, to the photochemically excited state of the photosensitizer (Type I 
E 
Fluorescence
Intersystem 
crossing 
1P* 
1P0 
Phosphorescence
3P*
Absorption 
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pathway), 3) preferential oxidation of guanine by singlet molecular oxygen (1O2) 
generated via energy transfer from the excited photosenstizer (Type II pathway).[35-38] 
 
Figure 3 Photocleavage by Type I & II Pathways. Once entered into an excited state, the sensitizer may 
transfer its energy to the ground triplet state of oxygen exciting oxygen to a singlet state via the Type II 
pathway.  Alternatively, the photosensitizer may be oxidized through the loss of an electron to a nearby 
species capable of accepting an electron such as a oxygen molecule.  This electron transfer may then induce 
deoxyribose hydrogen atom abstraction, via the production of cytotoxic hydroxyl radicals (·OH). The 
excited photosensitizer may also be reduced by accepting an electron from DNA. Although the Type I 
plays a relatively minor role in PDT compared to Type II, both can serve to damage DNA and other 
biomolecules which may subsequently induce necrosis and/or apoptosis of living cells.  
 
The triplet lifetime is defined as the average time a molecule spends in an excited 
triplet state. Having a long triplet lifetime is therefore a key factor in the development of 
new photosensitizers. The triplet state energy of the photosensitizer can then easily be 
transferred to another molecule which is located in close proximity. Oxygen (3O2) is one 
of the few molecules which possess a triplet ground state. The energy of the oxygen 
excited singlet state is 7900 cm-1. Therefore, molecules which have triplet states with 
hν 3P* P 1P* 
P*
1O2 
oxidation of G 
P•+ + O2•- 
3O2 
DNA 
Type I energy transfer 
3O2 
•OH 
Cytotoxcity
(P* excited state photosensitizer) 
e- transfer
P•- + G•+ 
DNA 
Type II
Fenton 
Mechanism 
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lower energy will be unable to excite molecular oxygen from its ground triplet state to the 
higher excited singlet state. It has also been noted that molecules with much greater 
energies, above 18,000 cm-1, can lead to unfavorable Franck-Condon factors, which may 
inhibit the transfer of energy between these two species.  Molecules with triplet state 
energies between 7900 and 18000 cm-1 are therefore needed to initiate a Type II 
photosensitization reaction for use in PDT. [34-37] Singlet oxygen is a strong electrophile, 
which can induce significant damage to surrounding tissue, diffusing as far as 100 nm 
during its lifetime. [38] 
Those molecules which do not possess sufficient energy to excite the molecular 
oxygen ground state may still be candidates for use in PDT by means of the alternative 
Type I pathway (Figure 3). This pathway involves a process in which direct transfer of 
electrons from DNA nucleobases to the photosensitized triplet occurs. The 
photosensitized triplet can also transfer electrons to ground state oxygen, 3O2, to form 
superoxide anion radicals (O2•-).  The superoxide anion radical production can lead to the 
formation of hydroxyl radicals by a Fenton mechanism.  As mentioned previously, 
hydroxyl radicals then cleave the DNA phosphodiester backbone by a mechanism that 
involves abstraction of hydrogen atoms from deoxyribose.[39] Both singlet oxygen and 
hydroxyl radicals can damage cellular components, including DNA, proteins and other 
macromolecules. This leads to the destruction of cells through apoptosis and/or necrosis. 
There is an indication that there may be additional therapeutic benefits arising 
from PDT.  Inaba et al. have shown that apoptotic cells often serve as triggers leading to 
various immune responses.  This is because they often produce antigens which are 
recognized by the immune system.  It is often the case, however, that cancer cells are not 
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sufficiently immunogenic to trigger this response in vivo.[40, 41] This is due in part to the 
fact that most tumor antigens are masked or made inaccessible by cancerous growths. It 
has been shown that even cellular extracts removed and purified from PDT treated mice 
have the ability to induce immunogenic response in untreated mice with tumors.  These 
antigens were found to persist for a period of time lasting up to five weeks following the 
initial treatment, although their quantities diminished significantly at longer time points.  
The fact that there does not appear to be a long-term retention of this response may 
explain why tumors often reoccur. As the levels of the antigens diminish, the immune 
response also appears to fade, and the conditions regress to their previous states. 
During the last two decades, there has been significant research focused on some 
of the other beneficial effects that photodynamic therapy might produce.  Much of the 
data suggest that photodynamic therapy may lead to damage or destruction of the micro 
vascular network surrounding diseased tissue.[39, 42-44]  This can subsequently lead to 
hypoxia and anoxia.[45-48]  This appears to be the pathway responsible for the beneficial 
effects of compounds such as psoralen, which is used to treat psoriasis and (to a lesser 
extent) eczema and vitiligo. 
The research described in this thesis is focused on the discovery of new 
compounds for use in PDT. Towards this end, we have evaluated the photo-induced DNA 
cleaving abilities of the series of acridine and phenazine-based chromophores shown in 
Figure 4.  
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Figure 4 Investigational Compounds. Compounds were synthesized and character by collaborator Prof. 
Antonio Lorente et al. at the Universidad de Alcalá, Spain. DNA binding and photocleavage by 2 and 6 
have been extensively characterized by Dr. Xia Yang and Dr. Beth Wilson, respectively.[52, 53]  Partial 
analyses of  2 and 6 have been included in this thesis for comparison purposes.  
 
The extended, aromatic ring systems of these compounds are expected to 
intercalate between adjoining base pairs in the DNA double-helix. We have shown that 
photocleavage of plasmid DNA is achieved at micromolar concentrations of compound 
under near physiological conditions of pH and temperature (pH 7.0 and 22 °C). The 
plasmid pUC19 was employed in this study because of its size and availability. This 
plasmid is an accessory chromosome isolated from the bacterium Escherichia coli. The 
cleaving agent can induce nicks into the supercoiled DNA, which is then transformed to 
its relaxed or nicked form. The compounds investigated were shown to produce frank 
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stand breaks in the plasmid DNA, which were visualized by employing nondenaturing 
agarose gel electrophoresis. The plasmid fragments of linear, supercoiled and nicked 
forms can be isolated and observed on agarose gels, because the supercoiled plasmid 
migrates through the gel at a faster rate than the relaxed and linear forms. 
Photosensitizers can theoretically produce either single-strand breaks (SSBs) or double-
strand breaks (DSBs). DSBs typically occur when two SSBs are located within 10 base 
pairs on opposite strands of the DNA helix.  
The photonucleases 3, 5, and 6 in Figure 4 were designed to chelate copper(II), 
which is intended to enhance binding and thereby induce increased levels of DNA  
photocleavage. This is significant in light of the broad distribution of copper in biological 
systems.[49, 50]  
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Methods and Materials 
General 
Calf thymus DNA (CT-DNA) was obtained from Invitrogen (Lot: 1147749A). 
The concentrations of the DNA were determined based on the Beer’s Law (1), 
 
 
where c is the concentration of CT-DNA , l represents the path length of the cell (1 cm), 
and ε260= 12,824 M-1 (bp) cm-1 for CT-DNA.[51] The measurements were taken in a total 
volume of 500 µL of ddH2O. Each of the samples was vortexed to mix and allowed to 
preequilibrate for 60 min before absorbance was measured. Spectral data on the 
intercalants were recorded with a UV-1601 UV-Visible Shimadzu Spectrophotometer.  
 The putative intercalants 1 through 6 (Figure 4) were synthesized in Professor 
Antonio Lorente’s laboratory at the Universidad de Alcalá, Spain. Superoxide dismutase 
(SOD), catalase, D-mannitol, D-sorbitol, sodium benzoate, sodium azide and ethidium 
bromide were purchased from Sigma-Aldrich. Agarose was obtained from Fisher 
Scientific.   
DNA photocleavage reactions were conducted in a Rayonet Photochemical 
Reactor fitted with eleven 24 Watt RPR-350 nm Rayonet lamps (The Southern New 
England Ultraviolet Company) for phenazine derivatives 1 to 4, or eight 40 Watt RPR-
419 nm Rayonet lamps for the acridine derivatives 5 and 6. Images of agarose gels were 
visualized using an UV transilluminator (VWR) set at 302 nm and photographs obtained 
with a Polaroid DS-43/GelCam camera fitted with type 667 film (VWR).  
 
lcAbsorbance ε= (1) 
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Large–Scale Plasmid Preparation 
A total of 50 µL of competent cells (E. coli XL-1 blue, Stratagene) was 
transformed with 1 µL pUC19 plasmid DNA (500 ng/ µL; Promega) by heat shocking the 
cells for 90 s at 42 ˚C.  Next, 1 mL SOB E. coli culture media (1 L solution: Bacto 
Tryptone 20.0 g, Yeast Extract 5.0 g,  NaCl Deionized H2O 0.5 g, 800.0 ml) was added 
and the solution was incubated while shaking at 37 ˚C for 1 h in a 1.5 mL Eppendorf tube. 
Two 2% agarose plates were prepared from 100 mL solutions of sterilized Luria-Bertani 
(LB) broth inoculated with ampicillin (60 µg/mL). A total of 50 µL of the SOB E.coli 
culture mixture was streaked onto the surface of each agarose plate. The two culture 
plates were incubated overnight at 37 ˚C. A single colony was selected and grown for 8 h 
at 37 ˚C in a 2 mL solution of ampicillin inoculated LB broth while shaking on a Labline 
shaker. A total of 1 mL of this solution was then added to each of two 500 mL solutions 
of the inoculated LB broth and shaken for 16 h on the Labline shaker. The solutions were 
then centrifuged at 18,000 rpm for 30 min, and the supernatants removed. Plasmid was 
extracted from the recovered cell pellets using a Qiagen Plasmid Maxi kit according to 
the manufacturer’s instructions. The concentration of the resulting purified DNA was 
measured using the Shimadzu UV-1601 spectrophotometer, using the extinction 
coefficient Є = 12824 bp·M-1·cm-1. DNA purity was determined based on equation (2). A 
ratio value of 1.8 or greater indicated that the DNA plasmid was considered to be free of 
protein contamination.[51] 
 
 
 
 
280
260
Abs
Abs
Purity = (2) 
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Gel-Shift Assay 
 To determine the concentration at which a dsDNA mobility shift could be 
detected using agarose gel electrophoresis, increasing concentrations of the four 
intercalants, 1, 3, 4, and 5 were mixed with 38.5 µM bp pUC19 DNA in 20 mM sodium 
phosphate buffer, pH 7.0, in a total volume of 20 µL. The solutions were equilibrated in 
the dark for 1 h and were then electrophoresed on a 1.0 % non-denaturing agarose gel at 
20 mV over 16 h. After electrophoresis, gels were stained with ethidium bromide (0.5 
µg/mL), visualized on a transilluminator set at 302 nm, and photographed with a Polaroid 
Gelcam. 
Thermal Melting Studies  
Thermal denaturation experiments were conducted using 30 µM bp of CT-DNA 
at a [compound]/[DNA] molar ratio of 0.5 in 20 mM phosphate buffer pH 7.0 using 
compounds 3, 4, and 5. (Compound 1 was excluded from this analysis due to thermal 
degradation above 60 ˚C.) All solutions were in a total volume of 3 mL prepared in 3 mL 
quartz cuvettes (Starna). Samples were equilibrated in dark for 1 h at room temperature 
then heated from 25 ˚C to 100 ˚C at a rate of 0.5 ˚C / min using a Peltier heat block, while 
the absorbance was monitored at 260 nm. 
 The absorbance data was normalized using the equation Anormailized = (A CT-DNA – 
A lowest)/ (Ahighest– A lowest). The normalized absorbance was then plotted as a function of 
temperature and the melting temperature was then determined from the maximum of the 
first-derivative plot. A change in the Tm was calculated based on the formula ∆Tm = Tm 
(CT-DNA + Compound) - Tm (CT-DNA). All data sets were processed using KaleidaGraph™ Version 
3.5 software. 
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Photocleavage Cleavage of dsDNA 
Typical reaction conditions involved 38.5 µM bp pUC19 dsDNA plasmid, 20 mM 
sodium phosphate buffer pH 7.0, and micromolar concentrations of halogen salts of 
intercalants in a total volume of 20 µL. The solutions were preequilibrated in the dark for 
1 h and were then were irradiated at room temperature under aerobic conditions in a 
ventilated Rayonet Photochemical Reactor. Irradiation wavelengths were selected based 
on the λmax of each compound.  Parallel reactions without compound and/or irradiation 
were run as controls. The reactions were then mixed with 3 µL of an aqueous loading 
buffer (0.25% xylene cyanol FF, 0.25% bromophenol blue, 15% Ficoll Type 400) and 
electrophoresed at 4 V/cm on a 1.0% agarose gel for 90 min. The TAE buffer solution 
contained ethidium bromide (0.5 µg/mL). Gel images were captured with a Polaroid 
Gelcam and then quantified with a Molecular Dynamics FluorImager SI Gel Imaging 
System (Molecular Dynamics). Background corrections were done through a local 
averaging method. To adjust for the decreased binding of ethidium bromide to 
supercoiled DNA as compared to the nicked and linear forms, the following formulae, 3 
and 4, were employed to calculate cleavage yields.[51] 
 
 
 
Concentration Profile Experiments 
100*
*22.1
%
DNAdSupercoileofVolumeDNAnickedofVolume
DNAnickedofVolumeDNANicked += (4) 
100*
*22.1
*22.1%
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 A series of 20 µL reactions was prepared containing 38.5 µM bp pUC19 DNA, 20 
mM sodium phosphate buffer pH 7.0, and increasing concentrations of halogen salts of 
intercalants 1, 2, 3, 4, 5 and 6. The samples were equilibrated in the absence of light for 
60 min and irradiated for 60 min at room temperature in a ventilated Rayonet 
Photochemical Reactor. Reaction products were resolved on a 1.0 % non-denaturing 
agarose gel and quantitated as described above. The DNA photocleavage conversion was 
calculated based on cleavage yields obtained in parallel reactions without irradiation 
using the equations 3 and 4. 
Time Course Profile Experiments 
 A series of 20 µL reactions was prepared containing 38.5 µM bp pUC19 DNA, 20 
mM sodium phosphate buffer pH 7.0, and optimal concentrations of halogen salts of 
intercalants 1, 3, 4, 5 and 6. The samples were incubated in the absence of light for 1 h 
and irradiated for time periods from 0 to 60 min in 10 min increments at room 
temperature in a ventilated Rayonet Photochemical Reactor. Reaction products were 
resolved on a 1.0 % non-denaturing agarose gel and quantitated as described above using 
equations 3 and 4. 
Scavenger Experiments  
A series of 20 µL reactions was prepared containing 38.5 µM bp pUC19 DNA, 20 
mM sodium phosphate buffer pH 7.0, and micromolar concentrations of halogen salts of 
intercalants 1, 2, 3, 4, 5 and 6. The samples were incubated in the absence of light for 1 h 
and irradiated in the presence of either 100 mM sodium azide, 100 mM sodium benzoate, 
50 units superoxide dismutase, 50 units catalase, 20 mM D-sorbitol, or 20 mM D-
mannitol for 50 min at room temperature in a ventilated Rayonet Photochemical Reactor. 
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Reaction production were resolved on a 1.0 % non-denaturing agarose gel and 
quantitated as described above. The percent inhibition of DNA photocleavage was 
calculated based on cleavage yields obtained in parallel reaction run without scavenger 
using equations 3, 4, and 5. 
 
Salt Inhibition Experiments  
A series of 20 µL reactions was prepared containing 38.5 µM bp pUC19 DNA, 20 
mM sodium phosphate buffer pH 7.0, and micromolar concentrations of halogen salts of 
intercalants 1, 2, 3, 4, 5 and 6 and 0 to 150 mM NaCl. The samples were incubated in the 
absence of light for 1 h and then were irradiated for 60 min at room temperature in a 
ventilated Rayonet Photochemical Reactor. Reaction products were resolved on a 1.0% 
non-denaturing agarose gel and quantitated as described above. The percent inhibition of 
DNA photocleavage was calculated based on cleavage yields obtained in parallel reaction 
run without salt using equations 3, 4, and 6. 
 
 
 
100*
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Results and Discussion 
DNA Binding Studies 
UV-Vis Spectrophometry 
The λmax of each of the compounds 1 to 6 was determined using 1 mM stock 
solutions of the putative intercalators, which were diluted to reach final concentrations of 
50 µM in a volume of 500 µL. Each of these solutions was equilibrated for 1 h, after 
which absorption spectra were recorded (Table 2; Figures 5 to 10).  
 
 Table 2 UV-Vis Absorption Data.  Solutions of 50 µM of compound with and without 10 µM calf-
thymus DNA were prepared in ddH2O and were incubated for 1 h in absence of light. Absorption spectra 
were acquired using a Shimadzu UV-1601 Spectrophotometer.   
1 EC-1-12 absorbance obtained in the presence of 1.0 % SDS:  λmax = 362 nm, Abs @ λmax = 653 mOD . 
2 EC-1-12 absorbance in table is very low due to possible aggregation of compound. 
 
Compounds 1, 2, 4, 5 and 6 showed a marked decrease in absorbance upon the 
addition of CT-DNA (Table 2). This may be indicative of the compounds binding to 
Compound λmax (nm) 
Abs @ λmax 
(mOD) 
λmax w/ CT-
DNA (nm) 
Abs @ λmax w/ 
CT-DNA 
(mOD) 
1 371 873 365 500 
2 371 1704 371 985 
3 362 23 1, 2 363 25 2 
4 364 622 364 507 
5 437 1451 451 1246 
6 452 488 462 414 
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DNA.  In addition, compounds 5, and 6 showed evidence of pronounced bathochromic 
shifts in their λmax values. This provides evidence supporting intercalation as a possible 
binding mode for these compounds. The absorbance of compound 3 was also recorded in 
the presence of 1.0 % SDS to disrupt aggregation. Thus, the absorbance at 362 nm the 
absence of SDS is significantly lower due to aggregation of the compound in buffer. 
When DNA is added, absorbance at 362 nm is unchanged.  
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Figure 5 UV-vis Absorption Spectra of Al-VII-30, Compound 1. Two 50 µM solutions of compound 1, 
one in ddH2O only and one with 10 µM CT-DNA in ddH2O, were incubated for 1 h in the absence of light.  
  24
 
0
0.5
1
1.5
2
200 300 400 500 600 700
FH-III-165 Absorption Spectra
FH-III-165
w/ CT-DNA
Ab
so
rb
an
ce
 (O
D
)
W avelength (nm)  
Figure 6 UV-vis Absorption Spectra of FH-III-165, Compound 2. Two 50 µM solutions of compound 2, 
one in ddH2O only and one with 10 µM CT-DNA in ddH2O, were incubated for 1 h in the absence of light.  
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Figure 7 UV-vis Absorption Spectra of EC-I-12, Compound 3. Three 50 µM solutions of compound 3, 
one in ddH2O only, one containing 1% SDS and one with 10 µM CT-DNA in ddH2O, were incubated for 1 
h in the absence of light.  
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Figure 8 UV-vis Absorption Spectra of EC-I-13, Compound 4. Two 50 µM solutions of compound 4, 
one in ddH2O only and one with 10 µM CT-DNA in ddH2O, were incubated for 1 h in the absence of light.  
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Figure 9 UV-vis Absorption Spectra of AF-I-50, Compound 5. Two 50 µM solutions of compound 5, 
one in ddH2O only and one with 10 µM CT-DNA in ddH2O, were incubated for 1 h in the absence of light.  
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Figure 10 UV-vis Absorption Spectra of MP-I-73, Compound 6. Two 50 µM solutions of compound 6, 
one in ddH2O only and one with 10 µM CT-DNA in ddH2O,were incubated for 1 h in the absence of light.  
 
Thermal Melting Assay 
 Thermal denaturation experiments were conducted for the putative intercalants 3, 
4, and 5, using 38.5 µM bp of CT-DNA at a [compound]/[DNA] molar ratio of 0.5 in 20 
mM phosphate buffer pH 7.0 (Figures 11 to 13). (Compound 1 was excluded from this 
analysis due to thermal degradation observed above 60 ˚C.) Absorbance at 260 nm was 
measured as a function of increasing temperature. The temperature was raised from 25 to 
100 ˚C at a rate of 0.5 ˚C per min with a Peltier block. Normalized absorbance was then 
plotted as a function of temperature and the melting temperature was then determined 
from the maxima of first-derivative plots. A change in the Tm of CT-DNA upon the 
addition of compound was calculated based on the equation ∆Tm = Tm (CD-DNA + Cmpd) - Tm 
(CT-DNA).  When a compound binds to double-helical DNA, the helix is usually stabilized 
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and the melting temperature increases as a function of the binding affinity of the 
compound. Therefore, the results of the Tm data suggest that the compounds bind to DNA 
with decreasing affinity as follows: 2 > 4 > 5 > 6 w/Cu(II) > 6 w/o Cu(II) > 3 (Table 3). 
 
Figure 11 Thermal Melting Assay EC-I-12, Compound 3. Experiments employed 38.5 µM bp of CT-
DNA at a [compound 3]/[DNA bp] molar ratio of 0.5 in 20 mM phosphate buffer pH 7.0. After incubation 
in dark for 2 h, the samples were heated from 25 ˚C to 100 ˚C at a rate of 0.5 ˚C / min using a Peltier heat 
block, while the absorbance was monitored at 260 nm.  
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Figure 12 Thermal Melting Assay EC-I-13, Compound 4. Experiments employed 38.5 µM bp of CT-
DNA at a [compound 4]/[DNA bp] molar ratio of 0.5 in 20 mM phosphate buffer pH 7.0. After incubation 
in dark for 2 h, the samples were heated from 25 ˚C to 100 ˚C at a rate of 0.5 ˚C / min using a Peltier heat 
block, while the absorbance was monitored at 260 nm.  
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Figure 13 Thermal Melting Assay AF-I-50, Compound 5. Experiments employed 38.5 µM bp of CT-
DNA at a [compound 5]/[DNA bp] molar ratio of 0.5 in 20 mM phosphate buffer pH 7.0, in the presence 
(♦) and absence (□)of equimolar CuCl2. After incubation in dark for 2 h, the samples were heated from 25 
˚C to 100 ˚C at a rate of 0.5 ˚C / min using a Peltier heat block, while the absorbance was monitored at 260 
nm. 
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Compound 
 (0.5 compound/DNA ratio) 
∆Tm (˚C) 
AL-VII-30 (1) N/A 
FH-III-165 1(2) 26 
EC-I-12 (3) 3 
EC-I-13 (4) 22 
AF-I-50 (5) 15 
MP-I-73 2 (6) 4; 10 [w/ Cu(II)] 
 
Table 3 Thermal Melting Assay. Experiments employed 38.5 µM bp of CT-DNA at a 
[compound]/[DNA] molar ratio of 0.5 in 20 mM phosphate buffer pH 7.0 using compounds: AF-I-50, EC-
I-12, EC-I-13. Samples were heated from 25 ˚C to 100 ˚C at a rate of 0.5 ˚C / min using a Peltier heat block, 
while the absorbance was monitored at 260 nm.  
1 Data obtain by Xia Yang at 10 mM potassium phosphate buffer pH 7.0 in the presence of 37.5 µM  CT-
DNA and 0.5 molar ratio [drug]/[DNA].[52]  
2 Data obtained by Beth Wilson at 20 mM sodium phosphate buffer pH 7.1 in the presence of 10 µM  6, 
and 15 µM bp CT-DNA. [53] 
 
Gel Mobility Shift Assay 
Intercalators stack in between the adjacent base pairs within the DNA molecule, 
causing it to unwind and extend its compact, double-helical structure. This extension in 
the strand length reduces the mobility of the DNA as it migrates through agarose gels. 
The behavior is usually characteristic of intercalating molecules. Molecules which bind to 
the grooves of DNA do not usually cause significant increases in strand length. Therefore, 
smaller changes in migration are typically observed.   
In the DNA mobility experiments described in this thesis, increasing 
concentrations of compound were equilibrated with DNA in the dark for 1 h and then 
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subjected to electrophoresis on 1.0 % agarose gels under low voltage. After being 
allowed to migrate for 24 h, the agarose gels were stained with ethidium bromide, and 
visualized with a UV transilluminator. The gels were then photographed with a Polaroid 
Gelcam. Notable shifts were observed for compounds 1, 4 and 5 (Figures 14, 16, and 17-
18), while no shift was seen in the case of compound 3 (Figure 15). The most significant 
shift was produced by compound 5, which was followed by compound 4 and then 1. It is 
worth mentioning that compound 5 displayed significant bathochromicity and 
hypochromicity (Table 2, Figure 9) and produced a significant increase in the Tm (Table 3, 
Figure 13) upon binding to DNA. 
 
Figure 14 Gel Mobility Assay, AL-VII-30, Compound 1. Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA in a 20 µL reaction 
volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
resolved by agarose gel electrophoresis over 24 h and stained with ethidium bromide for 1 h. 
5 10 3020 40 50 60 0 [AL-VII-30] µM 
Light  - - - - - - - - 
Supercoiled 
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Figure 15 Gel Mobility Assay, EC-I-12, Compound 3. Each of the samples was prepared in the presence 
of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA in a 20 µL reaction volume. The 
samples were allowed to preequilibrate at room temperature for 60 min and then were resolved by agarose 
gel electrophoresis overnight and stained with ethidium bromide for 1 h. 
 
 
 
Figure 16 Gel Mobility Assay, EC-I-13, Compound 4. Each of the samples was prepared in the presence 
of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA in a 20 µL reaction volume. The 
samples were allowed to preequilibrate at room temperature for 60 min and then were resolved by agarose 
gel electrophoresis overnight and stained with ethidium bromide for 1 h. 
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Light  - - - - - - - - - - 
Supercoiled 
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Figure 17 Gel Mobility Assay, AF-I-50, Compound 5 Broad Titration. Each of the samples was 
prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA in a 20 
µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then 
were resolved by agarose gel electrophoresis over 24 h and stained with ethidium bromide for 1 h. 
 
 
Figure 18 Gel Mobility Assay, AF-I-50, Compound 5 Narrow Titration. Each of the samples was 
prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA in a 20 
µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then 
were resolved by agarose gel electrophoresis overnight and stained with ethidium bromide for 1 h. 
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Photocleavage of pUC19 dsDNA, Concentration Titrations 
Once the λmax value of each compound had been determined, concentration 
evaluation experiments were conducted. The reaction mixtures contained a total volume 
of 20 µL and were prepared with 38.5 µM bp of pUC19 plasmid, 20 mM sodium 
phosphate buffer pH 7.0, and variable concentrations of compound. These experiments 
were conducted to determine the lowest concentration of each compound which was 
capable of achieving greater than or equal to 90% conversion of supercoiled plasmid to 
either the nicked and/or linear forms (Figure 19 to Figure 27). A summary of the results 
is shown in Table 4. For compounds 1 – 4, the Rayonet Photochemical Reactor was 
equipped with eleven 24 Watt RPR-350 nm Rayonet lamps, whereas, in the case of 
reactions involving compounds 5 and 6, and eight 40 Watt RPR-419 nm Rayonet lamps 
were used.  (The lamps were selected because their emission profiles strongly overlapped 
the absorption bands of the compounds being evaluated.) 
Compounds 3, 5, and 6 contain copper binding units. Therefore, each of these 
compounds was examined in the presence and absence of 1:1 ratios of copper(II). (Higher 
ratios of Cu(II) to compound were not found to provide any additional cleavage 
enhancement, while less enhancement was observed at lower ratios of Cu(II) to 
compound.) These experiments revealed that compounds 3, 5 and 6 all showed 
significant enhancements in the conversion of supercoiled pUC19 DNA into linear and 
nicked forms when irradiated in the presence of Cu(II) (Figure 22, 25, and 27). 
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Compound λmax (nm) 
Minimum Con. 
(µM) 
w/ Copper(II) 
(µM) 
AL-VII-30 (1) 371 4 N/A 
FH-III-165 (2) 371 0.4 N/A 
EC-I-12 (3) 362 40 20 
EC-I-13 (4) 364 8 N/A 
AF-I-50 (5) 437 5 5 
MP-I-73 (6) 452 >100 50 
 
Table 4 Concentration Minima. Minimum concentration of compounds required to produce ≥ 90% 
conversion of supercoiled pUC19 plasmid to nicked/linear forms. Compounds 1-4 were irradiated with 
eleven 350 nm lamps, while 5 and 6 were irradiated with eight 419 nm lamps.  Each of the samples was 
prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 
µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then 
were irradiated for 60 min in a ventilated Rayonet Photochemical Reactor under aerobic conditions. 
 
 
Figure 19 Concentration Titration, AL-VII-30, Compound 1. Minimum concentration of compound 1 
required for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms. Samples were 
irradiated with eleven 350 nm lamps.  Each of the samples was prepared in the presence of 20 mM sodium 
phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The samples were 
allowed to preequilibrate at room temperature for 60 min and then were  irradiated for 60 min in a 
ventilated Rayonet Photochemical Reactor under aerobic conditions. 
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linear 
0 
+ 
20 
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Figure 20 Concentration Titration, FH-III-165, Compound 2. Minimum concentration of compound 2 
required for ≥  90% conversion of supercoiled pUC19 plasmid to nicked/linear forms. Samples were 
irradiated with eleven 350 nm lamps.  Each of the samples was prepared in the presence of 20 mM sodium 
phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The samples were 
allowed to preequilibrate at room temperature for 60 min and then were irradiated for 60 min in a ventilated 
Rayonet Photochemical Reactor under aerobic conditions. 
 
 
Figure 21  Concentration Titration, EC-I-12 w/o Cu(II), Compound 3. Minimum concentration of 
compound 3 required for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms. Samples 
were irradiated with eleven 350 nm lamps.  Each of the samples was prepared in the presence of 20 mM 
sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The samples 
were then allowed to preequilibrate at room temperature for 60 min and then were irradiated for 60 min in a 
ventilated Rayonet Photochemical Reactor under aerobic conditions. 
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Figure 22 Concentration Titration, EC-I-12 w/Cu(II), Compound 3. Minimum concentration of 
compound 3 required for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms in the 
presence of 1:1 molar equivalents of Cu(II). Samples were irradiated with eleven 350 nm lamps.  Each of 
the samples was prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp 
pUC19 DNA, in a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature 
for 60 min and then were irradiated for 60 min in a ventilated Rayonet Photochemical Reactor under 
aerobic conditions. 
 
 
Figure 23 Concentration Titration EC-I-13, Compound 4. Minimum concentration of compound 4 
required for ≥  90% conversion of supercoiled pUC19 plasmid to nicked/linear forms. Samples were 
irradiated with eleven 350 nm lamps.  Each of the samples was prepared in the presence of 20 mM sodium 
phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The samples were 
allowed to preequilibrate at room temperature for 60 min and then were irradiated for 60 min in a ventilated 
Rayonet Photochemical Reactor under aerobic conditions. 
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Figure 24 Concentration Titration, AF-I-50, Compound 5. Minimum concentration of compound 5 
required for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms. Samples were 
irradiated with eight 419 nm lamps.  Each of the samples was prepared in the presence of 20 mM sodium 
phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The samples were 
allowed to preequilibrate at room temperature for 60 min and then were irradiated for 60 min in a ventilated 
Rayonet Photochemical Reactor under aerobic conditions.  
 
 
Figure 25 Concentration Titration, AF-I-50 w/CuCl2. Minimum concentration of compound 5 required 
for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms in the presence of equimolar 
copper(II). Samples were irradiated with eight 419 nm lamps.  Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction 
volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
irradiated for 60 min in a ventilated Rayonet Photochemical Reactor under aerobic conditions. 
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Figure 26 Concentration Titration, MP-I-73, Compound 6. Minimum concentration of compound 6 
required for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms in the absence of 
copper(II). Samples were irradiated with eight 419 nm lamps.  Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction 
volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
irradiated for 60 min in a ventilated Rayonet Photochemical Reactor under aerobic conditions. 
 
 
 
Figure 27 Concentration Titration, MP-I-73 with w/CuCl2. Minimum concentration of compound 6 
required for ≥ 90% conversion of supercoiled pUC19 plasmid to nicked/linear forms in the presence of  
equimolar copper(II). Samples were irradiated with eight 419 nm lamps.  Each of the samples was prepared 
in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL 
reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
irradiated for 60 min in a ventilated Rayonet Photochemical Reactor under aerobic conditions with eight 
419 nm lamps. 
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 In this series of experiments, the minimal concentration required for a 90% or 
greater conversion of supercoiled DNA to nicked or linear forms was identified for each 
of the compounds under investigation. In each case, the concentrations were in the 
micromolar range.  Compounds 3, 5 and 6 were also found to exhibit enhanced 
performance in the presence of 1:1 equivalents of copper(II). This is promising 
considering the importance of copper(II) and its distribution in biological systems.[49, 50] 
From the values obtain in these experiments, the compounds can be ranked in order of 
increasing photocleavage effiencies as follows: 2 > 1 ≈ 5 > 4 > 3 > 6. This ordering 
remains the same in the presence and absence of copper(II), with the exception of 
compound 5 which,  when in the presence of Cu(II), cleaves DNA more efficiently than 
compound 1. Interestingly, the ordering of Tm values in the absence of Cu(II) is:  2 > 4 > 
5 > 6 > 3. (The Tm value for 1 could not be determined due to decomposition of the 
compound.) Thus, for the majority of the compounds, the general trend is that 
photocleavage efficiency increases as a function of increasing Tm, which may reflect 
increasing binding affinity of the compounds to DNA.  
Photocleavage of pUC19 dsDNA, Time Course Experiments 
 Concentrations similar to those which were used to achieve ≥ 90% DNA cleavage 
during 60 min of irradiation were used to investigate cleavage kinetics. In this series of 
experiments, individual reactions were prepared and irradiated in 10 min increments. The 
reaction products were then resolved on 1.0 % agarose gels (Figures 28 to 36). Gel 
images were captured with a Polaroid Gelcam and then quantified with a Molecular 
Dynamics FluorImager SI Gel Imaging System (Molecular Dynamics). Background 
corrections were done through a local averaging method. 
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Figure 28 Time Course Experiment, AL-VII-30, Compound 1. Each of the samples was prepared in the 
presence of 5 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 
20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and 
then were irradiated at room temperature in a ventilated Rayonet Photochemical Reactor under aerobic 
conditions with eleven 350 nm lamps for time periods from 0-60 min. 
 
 
Figure 29 Time Course Experiment, AL-VII-30, Compound 2. Each of the samples was prepared in the 
presence of 0.5 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 
20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and 
then were irradiated at room temperature in a ventilated Rayonet Photochemical Reactor under aerobic 
conditions with eleven 350 nm lamps for time periods from 0-70 min. 
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Nicked 
Linear 
Light (min)  10 0 50 20 30 40 0 
AL-VII-30 [5 µM] + + + + + + + - 
% cleavage 19 99 49 99 67 83 15 22 
60 
Supercoiled 
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Light (min)  0 40 30 10 50 20 60 0 70 
[FH-III-165] 0.5 µM  + + + + + + + - + 
% cleavage 14 54 51 31 75 37 82 12 89 
70 
- 
26 
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Figure 30 Time Course Experiment, EC-I-12 w/o Cu(II), Compound 3  Each of the samples was 
prepared in the presence of 20 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp 
pUC19 DNA, in a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature 
for 60 min and then were irradiated at room temperature in a ventilated Rayonet Photochemical Reactor 
under aerobic conditions with eleven 350 nm lamps for time periods from 0-60 min. 
 
 
Figure 31 Time Course Experiment, EC-I-12, Compound 3  Each of the samples was prepared in the 
presence of 20 µM compound, and equimolar CuCl2, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM 
bp pUC19 DNA, in a 20 µL reaction volume. The samples were allowed to preequilibrate at room 
temperature for 60 min and then were irradiated at room temperature in a ventilated Rayonet 
Photochemical Reactor under aerobic conditions with eleven 350 nm lamps for time periods from 0-70 
min. 
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Nicked 
Linear 
Light (min)  70 40 30 0 50 10 20 60 0 70 
EC-I-12 [20 µM] - + + + + + + + - + 
% cleavage 39 85 78 24 95 51 64 94 11 98 
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EC-I-12 [20 µM] + + + + + + + + - 
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CuCl2  - - - - - - - - - 
Supercoiled 
Nicked 
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Figure 32 Time Course Experiment, EC-I-13, Compound 4  Each of the samples was prepared in the 
presence of 10 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 
20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and 
then were irradiated at room temperature in a ventilated Rayonet Photochemical Reactor under aerobic 
conditions with eleven 350 nm lamps for time periods from 0-70 min. 
 
 
Figure 33 Time Course Experiment, AF-I-50, Compound 5. Each of the samples was prepared in the 
presence of 5 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 
20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and 
then were irradiated at room temperature in a ventilated Rayonet Photochemical Reactor under aerobic 
conditions with eight 419 nm lamps for time periods from 0-60 min. 
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Figure 34 Time Course Experiment, AF-I-50 w/CuCl2, Compound 5. Each of the samples was prepared 
in the presence of 5 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, 
and 5 µM CuCl2 in a 20 µL reaction volume. The samples were allowed to preequilibrate at room 
temperature for 60 min and then were irradiated at room temperature in a ventilated Rayonet 
Photochemical Reactor under aerobic conditions with eight 419 nm lamps for time periods from 0-70 min. 
 
 
Figure 35 Time Course Experiment MP-I-73 w/o CuCl2, Compound 6.  Each of the samples was 
prepared in the presence of 50 µM compound, 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp 
pUC19 DNA, in a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature 
for 60 min and then were irradiated at room temperature in a ventilated Rayonet Photochemical Reactor 
under aerobic conditions with eight 419 nm lamps for time periods from 0-70 min. 
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Figure 36 Time Course Experiment MP-I-73 w/ Cu (II), Compound 6.  Each of the samples was 
prepared in the presence of 50 µM compound and 1:1 equiv CuCl2, 20 mM sodium phosphate buffer pH 
7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The samples were allowed to preequilibrate 
at room temperature for 60 min and then were irradiated at room temperature in a ventilated Rayonet 
Photochemical Reactor under aerobic conditions with eight 419 nm lamps for time periods from 0-70 min. 
Figure 37  Time Course Experiments. Time dependent analysis of the progression of photocleavage. 
Samples were prepared using the following concentrations of compound: Compound 1, 5 µM; Compound 
2, 0.5 µM; Compound 3, 20 µM; Compound 4, 10 µM; Compound 5, 5 µM; Compound 6, 50 µM. Each of 
the samples was prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp 
pUC19 DNA, in a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature 
for 60 min and then were irradiated at room temperature for 0-60 min in a ventilated Rayonet 
Photochemical Reactor under aerobic conditions. Compounds 1, 2, 3, and 4 were irradiated with eleven 350 
nm lamps, while 5 and 6 were irradiated with eight 419 nm lamps. 
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This series of experiments was employed to examine DNA photocleavage kinetics. 
From the data gathered at t = 10 min (Figure 37), the compounds can be ranked in order 
of decreasing rate as follows: 5 w/Cu > 5 w/o Cu > 3 w/ Cu > 4 > 6 w/Cu > 2 > 3 w/o Cu 
> 6 w/o Cu > 1.  
Photocleavage of pUC19 dsDNA, Radical Scavenger Assay 
To investigate the mechanism(s) involved in DNA photocleavage, we conducted 
inhibition experiments in which DNA photocleavage reactions were conducted in the 
presence of several scavengers: sodium azide for 1O2, catalase for H2O2, superoxide 
dismutase (SOD) for O2•-, D-mannitol, D-sorbitol, and sodium benzoate for •OH (Figures 
38 to 43). If the scavenger is successful in inhibiting DNA damage, then this should 
correspond to an increase in the amount of supercoiled DNA and a corresponding 
decrease in the quantity of the nicked and linear forms. A summary of the data obtained 
from these studies is in Table 5. 
 The results of this investigation strongly suggests that the photocleavage of DNA 
occurs as a result of a combinations of type I and type II mechanisms in the case of 
compounds 3, 5 and 6.  From the information obtain in this series of experiments, there is 
a suggestion that singlet oxygen may be involved in DNA photocleavage by all six 
investigational compounds due to the decrease in cleavage seen in the presence of the 
singlet oxygen scavenger sodium azide (Table 5). For the planar phenazine compound 3, 
there was also a significant inhibition in cleavage yields observed in the presence of the 
superoxide scavenger superoxide dismutase, as well as in the presence of the hydroxyl 
radical scavenger sodium benzoate. Compound 5 also exhibits reduced photocleavage in 
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the presence of the hydroxyl radical scavenger, sodium benzoate. Alternatively, 
photocleavage by compound 6 is strongly inhibited by the H2O2 scavenger catalase. 
 
Figure 38 Scavenger Assay AL-VII-30, Compound 1. Percent inhibition of DNA photocleavage in the 
presence of scavengers. Each of the samples was prepared in the presence of 20 mM sodium phosphate 
buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The following concentrations of 
scavengers were added: Na Azide - 100 mM, catalase - 50 Units, SOD - 50 Units, catalase + SOD - 50 
Units each, D-mannitol - 20 mM, D-sorbitol - 20 mM, Na Benzoate - 100 mM. Then, samples were 
allowed to preequilibrate at room temperature for 60 min and were irradiated for 50 min in a ventilated 
Rayonet Photochemical Reactor under aerobic condition. 
 
Figure 39 Scavenger Assay FH-III-165, Compound 2. Percent inhibition of DNA photocleavage in the 
presence of scavengers. Each of the samples was prepared in the presence of 20 mM sodium phosphate 
buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The following concentrations of 
scavengers were added: Na Azide - 100 mM, catalase - 50 Units, SOD - 50 Units, catalase + SOD - 50 
Units each, D-mannitol - 20 mM, D-sorbitol - 20 mM, Na Benzoate - 100 mM. Then, samples were 
allowed to preequilibrate at room temperature for 60 min and were irradiated for 50 min in a ventilated 
Rayonet Photochemical Reactor under aerobic condition.   
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Figure 40 Scavenger Assay EC-I-12, Compound 3. Percent inhibition of DNA photocleavage in the 
presence of scavengers. Each of the samples was prepared in the presence of 20 mM sodium phosphate 
buffer pH 7.0, 20 µM compound 3, equimolar copper chloride, and 38.5 µM bp pUC19 DNA, in a 20 µL 
reaction volume. The following concentrations of scavengers were added: Na Azide - 100 mM, catalase - 
50 Units, SOD - 50 Units, catalase + SOD - 50 Units each, D-mannitol - 20 mM, D-sorbitol - 20 mM, Na 
Benzoate - 100 mM. Then, samples were allowed to preequilibrate at room temperature for 60 min and 
were irradiated for 50 min in a ventilated Rayonet Photochemical Reactor under aerobic condition.    
 
 
Figure 41 Scavenger Assay EC-I-13, Compound 4. Percent inhibition of DNA photocleavage in the 
presence of scavengers. Each of the samples was prepared in the presence of 20 mM sodium phosphate 
buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The following concentrations of 
scavengers were added: Na Azide - 100 mM, catalase - 50 Units, SOD - 50 Units, catalase + SOD - 50 
Units each, D-mannitol - 20 mM, D-sorbitol - 20 mM, Na Benzoate - 100 mM. Then, samples were 
allowed to preequilibrate at room temperature for 60 min and were irradiated for 50 min in a ventilated 
Rayonet Photochemical Reactor under aerobic condition. 
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Figure 42  Scavenger Assay AF-I-50, Compound 5. Percent inhibition of DNA photocleavage in the 
presence of scavengers. Each of the samples was prepared in the presence of 20 mM sodium phosphate 
buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The following concentrations of 
scavengers were added: Na Azide - 100 mM, catalase - 50 Units, SOD - 50 Units, catalase + SOD - 50 
Units each, D-mannitol - 20 mM, D-sorbitol - 20 mM, Na Benzoate - 100 mM. Then, samples were 
allowed to preequilibrate at room temperature for 60 min and were irradiated for 50 min in a ventilated 
Rayonet Photochemical Reactor under aerobic condition. 
 
 
 
Figure 43 Scavenger Assay MP-I-73, Compound 6. Percent inhibition of DNA photocleavage in the 
presence of scavengers. Each of the samples was prepared in the presence of equimolar copper chloride, 
20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, in a 20 µL reaction volume. The 
following concentrations of scavengers were added: Na Azide - 100 mM, catalase - 50 Units, SOD - 50 
Units, catalase + SOD - 50 Units each, D-mannitol - 20 mM, D-sorbitol - 20 mM, Na Benzoate - 100 mM. 
Then, samples were allowed to preequilibrate at room temperature for 60 min and were irradiated for 50 
min in a ventilated Rayonet Photochemical Reactor under aerobic condition.     
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Table 5 Scavenger Assays. Percent inhibition of DNA photocleavage in the presence of scavenger. 
Each of the samples was prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM 
bp pUC19 DNA, in a 20 µL reaction volume. Next, the following concentrations of scavengers were added: 
Na Azide - 100 mM, catalase - 50 Units, SOD - 50 Units, catalase + SOD - 50 Units each, D-mannitol - 20 
mM, D-sorbitol - 20 mM, Na Benzoate - 100 mM, and the samples were allowed to preequilibrate at room 
temperature for 60 min and then were irradiated for 50 min in a ventilated Rayonet Photochemical Reactor 
under aerobic conditions. Compounds 2 and 6 were evaluated in the presence of equimolar concentrations 
of CuCl2. 
 
Photocleavage of pUC19 dsDNA, Salt Inhibition Assay 
The investigational compounds contain positive charges at physiological pH, 
which many assist in binding the compounds to the negatively charged DNA backbone.  
In order to investigate the effect of competitive ions on the ability of these compound to 
induce DNA damage, a series of assays was conducted in which increasing 
% Inhibition with Scavenger C
om
pound  
%
 C
leavage 
Na Azide 
(1O2) 
Catalase
(H2O2) 
SOD 
(O2•-) 
Catalase 
+ SOD 
D-
mannitol 
(•OH) 
D-
sorbitol 
(•OH) 
Na 
Benzoate
(•OH) 
1 94 % 31% 3% 0% 0% 3% 4% 21% 
2 99 % 36% 6% 14% 9% 0% 6% 9% 
3 98 % 67% 24% 53% 44% 4% 0% 88% 
4 95 % 35% 1% 3% 2% 3% 5% 1% 
5 97 % 12% 1% 2% 3% 1% 1% 27% 
6 95 % 30% 93% 12% 86% 7% 5% 0% 
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concentrations of sodium chloride were titrated into the DNA photocleavage reactions 
(Figures 44 to 52).  
 
Figure 44 Salt Challenge AL-VII-30, Compound 1. Each of the samples was prepared in the presence of 
20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, and 0-150 mM NaCl in a 20 µL 
reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
irradiated for 60 min in a ventilated Rayonet Photochemical Reactor with eleven 350 nm lamps. 
 
 
Figure 45 Salt Challenge FH-III-165, Compound 2. Each of the samples was prepared in the presence of 
20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, and 0-150 mM NaCl in a 20 µL 
reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
irradiated for 60 min at room temperature in a ventilated Rayonet Photochemical Reactor with eleven 350 
nm lamps. 
[AL-VII-30] 5 µM 
[NaCl] mM 
Light  
- 100 75 0 125 150 25 50 150 
+ + + + + - + + + 
Supercoiled 
Nicked 
Linear 
- + + + + + + + + 
% cleavage 10 27 28 98 31 11 25 26 26 
[FH-III-165] 0.5 µM 
[NaCl] mM 
Light  
- 100 75 0 125 150 25 50 150 
+ + + + + - + + + 
Supercoiled 
Nicked 
Linear 
- + + + + + + + + 
- 
- 
- 
% cleavage 18 57 63 94 57 7 82 64 50 6 
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Figure 46 Salt Challenge EC-I-12 w/o Cu (II), Compound 3. Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, 20 µM 3, and 0-150 
mM NaCl in a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 
60 min and then were irradiated for 60 min at room temperature in a ventilated Rayonet Photochemical 
Reactor with eleven 350 nm lamps. 
 
 
Figure 47 Salt Challenge EC-I-12 w/ Cu (II), Compound 3. Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0, equimolar copper chloride and 38.5 µM bp pUC19 
DNA, 20 µM 3, 1:1 of equiv CuCl2, and 0-150 mM NaCl in a 20 µL reaction volume. The samples were 
allowed to preequilibrate at room temperature for 60 min and then were irradiated for 60 min at room 
temperature in a ventilated Rayonet Photochemical Reactor with eleven 350 nm lamps. 
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Figure 48 Salt Challenge EC-I-13, Compound 4. Each of the samples was prepared in the presence of 20 
mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, and 0-150 mM NaCl in a 20 µL 
reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and then were 
irradiated for 60 min at room temperature in a ventilated Rayonet Photochemical Reactor with eleven 350 
nm lamps. 
 
 
 
Figure 49 Salt Challenge AF-I-50, Compound 5 w/o CuCl2. Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, and 0-150 mM NaCl in 
a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and 
then were irradiated for 60 min at room temperature in a ventilated Rayonet Photochemical Reactor with 
eight 419 nm lamps. 
 
 
[EC-I-13] 10 µM 
[NaCl] mM 
Light  
- 100 75 0 125 150 25 50 150 
+ + + + + - + + + 
Supercoiled 
Nicked 
Linear 
- + + + + + + + + 
- 
- 
- 
% cleavage 22 78 85 93 75 7 91 88 75 9 
Supercoiled 
Nicked 
Linear 
[NaCl] mM - 100 75 0 125 150 25 50 150 - 
Light  + + + + + - + + + - 
[AF-I-50] µM - + + + + + + + + - 
CuCl2 - - - - - - - - - - 
% cleavage 10 66 70 95 63 10 79 72 57 11 
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Figure 50 Salt Challenge AF-I-50, w/ CuCl2. Each of the samples was prepared in the presence of 20 mM 
sodium phosphate buffer pH 7.0, equimolar copper chloride and 38.5 µM bp pUC19 DNA, 5 µM CuCl2, 
and 0-150 mM NaCl in a 20 µL reaction volume. The samples were allowed to preequilibrate at room 
temperature for 60 min and then were irradiated for 60 min at room temperature in a ventilated Rayonet 
Photochemical Reactor with eight 419 nm lamps. 
 
 
 
Figure 51 Salt Challenge MP-I-73 w/o Cu (II), Compound 6. Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, and 0-150 mM NaCl in 
a 20 µL reaction volume. The samples were allowed to preequilibrate at room temperature for 60 min and 
then were irradiated at room temperature for 60 min in a ventilated Rayonet Photochemical Reactor with 
eight 419 nm lamps. 
Nicked 
Linear 
[NaCl] mM - 100 75 0 125 150 25 50 150 - 
Light  + + + + + - + + + - 
[MP-I-73] 50 µM - + + + + + + + + - 
% cleavage 
CuCl2 - - - - - - - - - - 
Supercoiled 
29 32 49 28 16 38 33 24 17 25 
Supercoiled 
Nicked 
Linear 
[NaCl] mM - 100 75 0 125 150 25 50 150 - 
Light  + + + + + - + + + - 
[AF-I-50] µM - + + + + + + + + - 
% cleavage 10 66 70 95 63 10 79 72 57 11 
CuCl2 + + + + + + + + + + 
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Figure 52 Salt Challenge MP-I-73 w/ Cu (II), Compound 6. Each of the samples was prepared in the 
presence of 20 mM sodium phosphate buffer pH 7.0, equimolar copper chloride and 38.5 µM bp pUC19 
DNA,equimolar copper(II), and 0-150 mM NaCl in a 20 µL reaction volume. The samples were allowed to 
preequilibrate at room temperature for 60 min and then were irradiated at room temperature for 60 min in a 
ventilated Rayonet Photochemical Reactor with eight 419 nm lamps. 
Table 6 Salt Inhibition Assays, Percent inhibition in the Presence of NaCl. Each of the samples was 
prepared in the presence of 20 mM sodium phosphate buffer pH 7.0 and 38.5 µM bp pUC19 DNA, and 0-
150 mM NaCl in a 20 µL reaction volume. The samples were allowed to preequilibrate at room 
temperature for 60 min and then were irradiated for 60 min in a ventilated Rayonet Photochemical Reactor 
under aerobic conditions. Compounds  3, 5, and 6 were also tested in the presence of equimolar copper(II). 
[Salt] 
C
om
po
un
d 
25 mM 50 mM 75 mM 100 mM 125 mM 150 mM 
1 83% 82% 79% 81% 76% 82% 
2 16% 40% 41% 49% 49% 58% 
w/oCu 21% 18% 32% 50% 57% 67% 3 
w/Cu 13% 12% 21% 25% 28% 23% 
4 0% 7% 11% 21% 25% 25% 
w/oCu 19% 27% 29% 34% 38% 45% 5 
w/Cu 17% 33% 36% 36% 49% 55% 
w/oCu 46% 67% 67% 83% 88% 99% 6 
w/Cu 10% 14% 20% 23% 40% 35% 
Nicked 
Linear 
[NaCl] mM - 100 75 0 125 150 25 50 150 - 
Light  + + + + + - + + + - 
[MP-I-73] 50 µM - + + + + + + + + - 
% cleavage 21 75 77 91 63 7 84 81 67 18 
CuCl2 + + + + + - + + + + 
Supercoiled 
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In the case of compounds 1, 2, 3 w/o copper, 5 and 6 w/o copper, moderate to 
significant reductions in the amount of nicked and linear DNA were observed as the 
concentration of NaCl was increased. In comparison, compounds 3 and 4 were more 
robust and remained relatively unaffected when NaCl concentration was increased. In 
both cases, the % inhibition values were 23% in the presence of 150 mM NaCl.  
 In this series of experiments, the effect of sodium counter cations on the ability of 
the investigational compounds to photoconvert supercoiled DNA to nicked or linear 
forms was examined. In each case, the increasing concentrations of sodium chloride were 
in the titrated into reaction mixtures. The percent inhibition induced by the competitive 
sodium cations was calculated using formula 6. From the values obtained in these 
experiments, the compounds can be ranked according to their abilities to achieve highest 
cleavage in the presence of physiological concentrations of sodium chloride (150 mM) as 
follows: 3 (w/ Cu(II)) > 4 > 6 (w/ Cu (II)) > 5 (w/o Cu (II)) ≈ 5 (w/ Cu (II)) > 2 > 3 (w/o 
Cu (II)) > 1 > 6 (w/o Cu(II)). 
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Conclusions 
In this thesis, we describe several phenazine and acridine-based intercalators that 
are able to effectively mediate photocleavage of pUC19 plasmid DNA through a 
combination of type one and/or type two photocleavage pathways. Compound 5 proved 
to be the most effective DNA photocleaver, followed by 2, 4, 3, 6 and finally 1, when 
thermal stability and ability to cleave at physiological concentrations of NaCl is taken 
into account. Tm data have been presented, suggesting strong binding of compounds 2, 4, 
and 5 to double-helical DNA. (In the Tm measurements the compounds were ordered 
based upon their ability to bind CT-DNA as follows, 2 >  5 w/Cu(II) > 1 ≈ 5 w/o Cu(II) 
> 4 > 3 > 6 w/Cu(II) > 6 w/o Cu(II). In general, photocleavage activity was found to 
show a strong correlation to ∆Tm values. The viologen linker employed in the reference 
compound 2 was found to induce superior binding and photocleavage compared to the 
more flexible linker employed in its analogue compound 1. Additionally, the smaller 
more constrained pyridine linker employed in compound 5 was determined to be superior 
to the longer pyridine linker employed in the analogous compound 6 in terms of overall 
photocleavage efficiency. In an attempt to evaluate how photo-induced damage and 
DNA-binding might be affected by competitive ions, a series of salt inhibition 
experiments was conducted. We have demonstrated that compounds 3 w/Cu and 4 show 
the most robust photocleavage when challenged with physiological concentrations of 
sodium chloride. Several of the compounds were designed to bind copper. Thus, copper 
was found to induce significant enhancement in DNA photocleavage by all three putative 
copper binding compounds (3, 5 and 6). It is notable that the metal binding planar 
compound 3 was the most resistant to inhibition induced by competitive sodium cations.  
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Among the four new compounds investigated in this thesis (1, 3, 4, and 5), I have 
found that the linked bis-acridine derivative 5 (AF-I-50) possesses the highest potential 
for use in PDT. This determination was based upon the ability of this compound to 
effectively induce ≥ 90 % photocleavage in pUC19 DNA at concentrations as low as 5 
µM. Compound 5 demonstrated significant DNA binding as indicated by pronounced 
bathochromicity and hypochromicity, its large ∆Tm value as well as by the changes in 
DNA mobility noted in gel shift assays. In addition, compound 5 induced 
photoconversion of DNA at high levels when challenged with sodium chloride. 
Compound 5 demonstrated good results the binding studies, and also exhibited robust 
performance through the entire series of experiments, and is therefore considered to be 
the most promising of the new compounds. This helps support the idea of structure-based 
drug design as an effective method to develop new and more effective DNA-
photocleavage agents.  
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